N/A N=40 Randomized Double-blind Treatment

Incentive-based and Media Literacy Informed Approaches to Improve Vaping Cessation

Behavior, Health Risk · Implementation Science · E Cigarette Use · Cessation, Smoking · Incentives

Bottom Line

View on ClinicalTrials.gov: NCT05586308 ↗

Enrolled (actual)

Serious AEs

—

Results posted

Jan 2026

Primary outcome: Primary: Engagement_remote checkin_3 — 6; 5; 6; 5 Participants — p=0.820

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Text-massaging suport (Behavioral); Financial incentive (Behavioral); Media literacy (Behavioral)
Age: Adult · 19+ yrs
Sex: All
Sponsor: University of Nebraska
Primary completion: Nov 2024

Outcome Measures

Outcome	Result	p-value
PRIMARY Engagement_remote checkin_3	6; 5; 6; 5; 3; 6	0.820
PRIMARY Retention	6; 5; 5; 5; 3; 6	—
SECONDARY Biochemically Verified Vaping Abstinence	2; 0; 0; 2; 4; 5	—
SECONDARY Self-reported Vaping Abstinence	2; 3; 1; 2; 4; 2	—

Summary

This study aims to evaluate the feasibility and compare the preliminary effect of vaping cessation program consisting of media literacy education and real-time text messaging support and leverage insights from behavioral economics to enhance social and financial incentives to improve program engagement, and eventually abstinence. Our hypotheses are that 1) the Combined arm is associated with improved vaping abstinence to the Media literacy and Financial incentive arms; and 2) the financial incentive-related arms (either Combined or Financial incentive) enhance engagement compared to the non-incentive related arms.

Eligibility Criteria

Inclusion Criteria

Aged 19-29
Report vaping in the previous 30 days
Have access to internet/video chat/SMS text message
Are interested in quitting vaping in the next 30 days

Exclusion Criteria

Must meet all the inclusion criteria
Self-report as currently pregnant or planning to become pregnant in the next 3 months
Already involved in vaping cession programs (either behavioral or medical intervention)

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05586308). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.